vorinostat and Di Guglielmo Disease studies

vorinostat and Di Guglielmo Disease

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

Excerpt	Relevance	Reference
"Murine erythroleukemia cells developed for resistance to SAHA are cross-resistant to trichostatin A, a known deacetylase inhibitor and differentiation inducer, but are not cross-resistant to HMBA."	1.30	A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. ( Breslow, R; Emiliani, S; Marks, PA; Richon, VM; Rifkind, RA; Verdin, E; Webb, Y, 1998)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

1 (50.00)

18.2507

2000's

1 (50.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Richon, VM	1
Emiliani, S	1
Verdin, E	1
Webb, Y	1
Breslow, R	1
Rifkind, RA	1
Marks, PA	1
Ruefli, AA	1
Bernhard, D	1
Tainton, KM	1
Kofler, R	1
Smyth, MJ	1
Johnstone, RW	1

Studies

Richon, VM

Emiliani, S

Verdin, E

Webb, Y

Breslow, R

Rifkind, RA

Marks, PA

Ruefli, AA

Bernhard, D

Tainton, KM

Kofler, R

Smyth, MJ

Johnstone, RW

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]	Phase 1	6 participants (Actual)	Interventional	2016-03-31	Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]

Phase 1

6 participants (Actual)

Interventional

2016-03-31

Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

2 other studies available for vorinostat and Di Guglielmo Disease

Article	Year
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America, 1998, Mar-17, Volume: 95, Issue:6 Topics: Acetamides; Animals; Carcinoma; Cell Differentiation; Cell Line, Transformed; Cell Transformation, N	1998
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. International journal of cancer, 2002, May-10, Volume: 99, Issue:2 Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3	2002

Article

Year

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Proceedings of the National Academy of Sciences of the United States of America, 1998, Mar-17, Volume: 95, Issue:6

Topics: Acetamides; Animals; Carcinoma; Cell Differentiation; Cell Line, Transformed; Cell Transformation, N

1998

Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.

International journal of cancer, 2002, May-10, Volume: 99, Issue:2

Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3

2002